| Literature DB >> 31673142 |
Chong-Yin Huang1,2, Kun Yang1,2, Jun-Jie Cao1,2, Yu-Juan Li1,2, Zi-Yuan Wang1,2, Hui Yu1,2, Zhi-Liang Sun1,2, Xiaofeng Zheng1,2, Zhao-Ying Liu3,4.
Abstract
Gelsemium elegans is a flowering plant in the Loganiaceae. Because it can promote the growth of pigs and sheep, it is widely used, including in veterinary clinics, but little information is available about its biological effects. Here, we used high-throughput sequencing to characterize the differentially expressed genes (DEGs) in the ileums of pigs between a control group and a group fed Gelsemium elegans for 45 days. We found that Gelsemium elegans affected many inflammatory and immune pathways, including biological processes such as defense responses, inflammation and immune responses. Moreover, this study identified several important genes related to the anti-inflammatory activity of Gelsemium elegans (e.g., CXCL-8, IL1A, and CSF2), which will be beneficial for further study of the pharmacological mechanisms and clinical applications of Gelsemium elegans.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31673142 PMCID: PMC6823445 DOI: 10.1038/s41598-019-52374-4
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Statistics from digital gene expression sequencing.
| Sample_name | C1 | C2 | C3 | G1 | G2 | G3 |
|---|---|---|---|---|---|---|
| Raw reads | 53351960 | 52203452 | 62621280 | 50860180 | 53702840 | 40267710 |
| Clean reads | 52354682 | 50836840 | 61569634 | 49898956 | 52727580 | 39636068 |
| Clean bases (Gb) | 7.39 | 7.24 | 8.70 | 7.05 | 7.49 | 5.63 |
| Q20(%) | 97.10% | 96.95% | 97.10% | 96.80% | 96.95% | 97.45% |
| Q30(%) | 92.20% | 91.90% | 92.20% | 91.60% | 91.80% | 92.95% |
| Total mapped | 50591699 (96.60%) | 49185332 (96.80%) | 58949697 (95.70%) | 47391403 (95%) | 50409079 (95.60%) | 38280432 (96.60%) |
| Multiple mapped | 2682859 | 2066081 | 3841841 | 3278765 | 3483805 | 2173146 |
| Uniquely mapped | 47908840 | 47119251 | 55107856 | 44112638 | 46925274 | 36107286 |
| Reads map to ‘+‘ | 23954389 | 23559590 | 27553907 | 22056319 | 23462604 | 18053653 |
| Reads map to ‘-‘ | 23954451 | 23559661 | 27553949 | 22056319 | 23462670 | 18053633 |
| Non-Splice reads | 26179110 | 26211625 | 31002946 | 24250115 | 26227333 | 20306368 |
| Splice reads | 21729730 | 20907626 | 24104910 | 19862523 | 20697941 | 15800918 |
C1~3: ileum tissue samples from the control group; G1~3: ileum tissue samples from the experimental group.
The number of genes in different FPKM expression intervals in all samples.
| Group | FPKM interval | |||||
|---|---|---|---|---|---|---|
| 0~1 | 1~5 | 5~10 | 10~20 | 20~50 | >50 | |
| C1 | 7510 (37.81%) | 4396 (22.13%) | 2955 (14.88%) | 2350 (11.83%) | 1690 (8.51%) | 961 (4.84%) |
| C2 | 7754 (39.04%) | 4578 (23.05%) | 2760 (13.9%) | 2268 (11.42%) | 1525 (7.68%) | 977 (4.92%) |
| C3 | 8249 (41.53%) | 4632 (23.32%) | 2622 (13.2%) | 2040 (10.27%) | 1403 (7.07%) | 916 (4.61%) |
| G1 | 8087 (40.72%) | 4722 (23.77%) | 2785 (14.02%) | 2066 (10.4%) | 1360 (6.85%) | 842 (4.24%) |
| G2 | 8035 (40.45%) | 4641 (23.37%) | 2718 (13.68%) | 2156 (10.85%) | 1416 (7.12%) | 896 (4.51%) |
| G3 | 7602 (38.27%) | 4620 (23.26%) | 2905 (14.63%) | 2380 (11.98%) | 1467 (7.39%) | 888 (4.47%) |
Figure 1GO classifications of the differentially expressed genes in intestinal tissues from the Gelsemium elegans group and the control group. The differentially expressed genes were classified into three categories: biological process, cellular component, and molecular function.
Figure 2Pathway enrichment results of the differentially expressed genes. The X-axis represents the enrichment factor value, and the Y-axis represents the pathway name. The color represents the P-value (significance: P ≤ 0.05), and the size of the point represents the number of genes. The enrichment factor represents the ratio of the enriched genes to the background genes.
Pathway enrichment gene expression.
| Gene symbol | Gene description | Gene ID | Gene family | Log2(Fold Change) | P value |
|---|---|---|---|---|---|
| IL1A | interleukin 1 alpha | ENSSSCG00000008090 | IL-1 family | −1.12 | 0.0063 |
| IL1RL2 | interleukin 1 receptor like 2 | ENSSSCG00000023550 | — | 3.55 | 0.0002 |
| IL20RA | interleukin 20 receptor subunit alpha | ENSSSCG00000004157 | chemokine receptor family | −1.16 | 0.0146 |
| IL5RA | interleukin 5 receptor subunit alpha | ENSSSCG00000011528 | chemokine receptor family | −1.36 | 0.0191 |
| CCL28 | C-C motif chemokine ligand 28 | ENSSSCG00000016871 | Intercrine beta(chemokine CC)family | −1.37 | <0.0001 |
| CCR2 | C-C chemokine receptor type 2 | ENSSSCG00000024311 | — | −1.16 | <0.0001 |
| TNFRSF11A | TNF receptor superfamily member 11a | ENSSSCG00000004898 | tumor necrosis factor receptor superfamily | −1.15 | <0.0001 |
| LTA | Sus scrofa lymphotoxin alpha (LTA), mRNA. | ENSSSCG00000001403 | tumor necrosis factor family. | 2.61 | 0.0289 |
| CSF2 | granulocyte-macrophage colony-stimulating factor precursor | ENSSSCG00000023737 | GM-CSF family | −2.02 | 0.0003 |
| FOS | proto-oncogene c-Fos | ENSSSCG00000002383 | FOS subfamily | 1.06 | <0.0001 |
| CXCL8 | Sus scrofa C-X-C motif chemokine ligand 8 (CXCL8), mRNA. | ENSSSCG00000008953 | CXC chemokine family | −1.21 | 0.0007 |
| CXCL2 | C-X-C motif chemokine 2 precursor | ENSSSCG00000008959 | CXC chemokine family | −1.73 | 0.0011 |
| AMCF-II | Alveolar macrophage chemotactic factor 2 | ENSSSCG00000008957 | CXC chemokine family | −2.17 | <0.0001 |
| INHBA | Inhibin beta A chain | ENSSSCG00000035077 | TGF-β family | −1.09 | 0.0083 |
| DEFB1 | Sus scrofa defensin beta 1 (DEFB1), mRNA. | ENSSSCG00000029990 | Beta-defensin family | 1.67 | 0.0051 |
| S100A8 | Sus scrofa S100 calcium binding protein A8 (S100A8), mRNA. | ENSSSCG00000006590 | S-100 family | −3.05 | 0.0074 |
| ANPEP | alanyl aminopeptidase, membrane | ENSSSCG00000001849 | peptidase M1 family | 1.01 | 0.0113 |
| CD38 | ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 | ENSSSCG00000008742 | ADP-ribosyl cyclase family | −1.03 | <0.0001 |
| C4BPB | complement component 4 binding protein beta | ENSSSCG00000015661 | — | −1.64 | <0.0001 |
| C4BPA | Sus scrofa complement component 4 binding protein, alpha (C4BPA), mRNA. | ENSSSCG00000015662 | — | −1.18 | 0.0110 |
| C8G | complement C8 gamma chain | ENSSSCG00000005840 | calycin superfamily | 2.17 | 0.0217 |
| F11 | — | ENSSSCG00000032653 | peptidase S1 family | −1.71 | 0.0241 |
| C2 | complement C2 | ENSSSCG00000001422 | peptidase S1 family | −1.01 | <0.0001 |
| C3 | complement C3 | ENSSSCG00000013551 | — | −1.52 | 0.0006 |
| C5 | complement C5 | ENSSSCG00000005512 | — | −1.26 | 0.0010 |
| NFKBIZ | NFKB inhibitor zeta | ENSSSCG00000011951 | — | −1.19 | <0.0001 |
Figure 3Relative expression of the candidate genes by qRT-PCR. Three samples were included in each group, and three replicates for each sample were performed. The relative expression level was measured by qRT-PCR. These data are expressed as the mean ± SD relative to the control. aP < 0.05 compared with the control group.
Composition and nutritional level of the complete diet.
| Ingredients | Ratio (%) |
|---|---|
| Corn | 52.99 |
| Expanded corn | 10.00 |
| Soybean meal | 20.00 |
| Fish meal | 1.50 |
| Soybean oil | 0.80 |
| Fine powder | 0.72 |
| Salt | 0.30 |
| Sucrose | 2.50 |
| Premixa | 2.59 |
| Total | 100.00 |
|
| |
| DE (MJ/kg) | 14.20 |
| Crude Protein(%) | 19.00 |
| Calcium (%) | 0.80 |
| Available phosphorus (%) | 0.50 |
| Lysine (%) | 1.40 |
| Methionine (%) | 0.84 |
| L-Threonine (%) | 0.40 |
(a)Premix is provided per kilogram of daily ration: VA 2200 IU; VD 220 IU; VE 62 mg; VK3 3.00 mg; VB1 3.00 mg; VB6 3.60 mg; VB12 0.02 mg; Biotin 0.45 mg; Pantothenic acid 10 mg; Nicotinic acid 30 mg; Choline chloride 500 mg; Mn 50 mg; Fe 150 mg; Zn 2200 mg; Cu 200 mg; I 0.3 mg; Se 0.3 mg. (b)The crude protein level in the table is the measured value, and the other is the calculated value.